IMATINIB Side Effects

7010024-6 | Eyelid Oedema, Haematotoxicity, Tumour Excision
on Sep 10, 2010 Female patient from JAPAN , 62 years of age, was diagnosed with gastrointestinal stromal tumour and was treated with Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: eyelid oedema, haematotoxicity, tumour excision. Imatinib dosage: 400 Mg.

7009487-1 | Hepatic Mass, Hypoglycaemia, Insulin-like Growth Factor Increased
Patient was taking Imatinib (View Usage). Patient had the following side effects: hepatic mass, hypoglycaemia, insulin-like growth factor increased on Sep 09, 2010 from KOREA, REPUBLIC OF Additional patient health information: Male patient , 72 years of age, weighting 114.6 lb, was diagnosed with gastrointestinal stromal tumour, hypoglycaemia and. Imatinib dosage: 200 Mg, Unk. During the same period patient was treated with DEXAMETHASONE (1 Mg/ Day) (View Dexamethasone Review and Dexamethasone Label ), ANTIHYPERTENSIVES (View Antihypertensives Review and Antihypertensives Label ).

6987406-1 | Hepatic Mass, Hypoglycaemia, Insulin-like Growth Factor Increased
Adverse event was reported on Sep 02, 2010 by a Male patient taking Imatinib (View Usage) (Dosage: 200 Mg, Unk) was diagnosed with gastrointestinal stromal tumour, hypoglycaemia and. Location: KOREA, REPUBLIC OF , 72 years of age, After Imatinib was administered, patient had the following side effects: hepatic mass, hypoglycaemia, insulin-like growth factor increased. During the same period patient was treated with DEXAMETHASONE (1 Mg/ Day) (View Dexamethasone Review and Dexamethasone Label ), ANTIHYPERTENSIVES (View Antihypertensives Review and Antihypertensives Label ).

6980488-2 | Gene Mutation Identification Test Positive, Malaise, Neutrophilia, Platelet Count Increased, Splenomegaly, White Blood Cell Count Increased
on Aug 31, 2010 Male patient from UNITED STATES , 63 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: gene mutation identification test positive, malaise, neutrophilia, platelet count increased, splenomegaly, white blood cell count increased. Imatinib dosage: 400 Mg Daily.


6979136-7 | Disseminated Intravascular Coagulation, Pulmonary Alveolar Haemorrhage, Renal Failure Acute, Tumour Lysis Syndrome
on Sep 07, 2010 Female patient from JAPAN , 83 years of age, was treated with Imatinib (View Usage). Patient had the following side effects: disseminated intravascular coagulation, pulmonary alveolar haemorrhage, renal failure acute, tumour lysis syndrome. Imatinib dosage: 100 Mg Daily. During the same period patient was treated with STEROIDS NOS (Unk) (View Steroids Nos Review and Steroids Nos Label ).

6959322-2 | Abortion Spontaneous
Patient was taking Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: abortion spontaneous on Dec 07, 2009 from AUSTRALIA Additional patient health information: Female patient , 23 years of age, was diagnosed with gastrointestinal stromal tumour and. Imatinib dosage: 400 Mg/day. During the same period patient was treated with NEUPOGEN (View Neupogen Review and Neupogen Label ), EPOETIN ALFA (View Epoetin Alfa Review and Epoetin Alfa Label ).

6941351-6 | Cerebrovascular Accident, Gene Mutation Identification Test Positive, Ischaemia, Platelet Count Increased, Polycythaemia Vera
Adverse event was reported on Aug 11, 2010 by a Male patient taking Imatinib (View Usage) (Dosage: 400 Mg Daily) was diagnosed with chronic myeloid leukaemia and. Location: UNITED STATES , 67 years of age, Patient experienced the following unwanted or unexpected effects: cerebrovascular accident, gene mutation identification test positive, ischaemia, platelet count increased, polycythaemia vera.

6914928-1 | Blast Cell Count Increased, Bone Marrow Failure, Interstitial Lung Disease, Pneumonitis
on Aug 04, 2010 Male patient from JAPAN , 74 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). Patient had the following side effects: blast cell count increased, bone marrow failure, interstitial lung disease, pneumonitis. Imatinib dosage: Unk. During the same period patient was treated with VINCRISTINE (Unk) (View Vincristine Review and Vincristine Label ), PREDNISOLONE (Unk) (View Prednisolone Review and Prednisolone Label ).

6905455-6 | Craniectomy, Dermatofibrosarcoma, Fatigue, Intra-cranial Lesion Excision, Malignant Tumour Excision, Nausea, Neoplasm Recurrence, Skin Graft, Transplant
on Jul 22, 2010 Male patient from UNITED STATES , 58 years of age, was diagnosed with dermatofibrosarcoma and was treated with Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: craniectomy, dermatofibrosarcoma, fatigue, intra-cranial lesion excision, malignant tumour excision, nausea (What is nausea?), neoplasm recurrence, skin graft, transplant. Imatinib dosage: 400 Mg, Bid.

6895487-9 | Gene Mutation Identification Test Positive, Leukopenia, Therapeutic Response Decreased, Thrombocytopenia
Patient was taking Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: gene mutation identification test positive, leukopenia, therapeutic response decreased, thrombocytopenia on Jul 23, 2010 from GERMANY Additional patient health information: Female patient , 47 years of age, was diagnosed with chronic myeloid leukaemia and. Imatinib dosage: 400 Mg Daily. During the same period patient was treated with ARA C (40 Mg Every 5 Days) (View Ara-c Review and Ara-c Label ).

6887796-4 | Bone Lesion, Bone Marrow Necrosis, Metastases To Heart, Metastases To Pleura, Metastases To The Mediastinum
Adverse event was reported on Jul 16, 2010 by a Male patient taking Imatinib (View Usage) (Dosage: 400 Mg Per Day) was diagnosed with gastrointestinal stromal tumour and. Location: FRANCE , 44 years of age, Patient had the following side effects: bone lesion, bone marrow necrosis, metastases to heart, metastases to pleura, metastases to the mediastinum.

6866713-7 | Abdominal Pain, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Intentional Overdose, Lip Swelling, Nausea, Neutrophil Count Decreased, Pyrexia
on Sep 24, 2007 Female patient from INDIA , 21 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), alanine aminotransferase increased, aspartate aminotransferase increased, intentional overdose, lip swelling, nausea (What is nausea?), neutrophil count decreased, pyrexia. Imatinib dosage: 400 Mg/d. Patient was hospitalized.

6844808-1 | Acute Lymphocytic Leukaemia Recurrent, Bone Marrow Transplant, Stem Cell Transplant
on Jul 01, 2010 Female patient from KOREA, REPUBLIC OF , 23 years of age, was diagnosed with acute lymphocytic leukaemia, graft versus host disease and was treated with Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: acute lymphocytic leukaemia recurrent, bone marrow transplant (What is bone marrow transplant?), stem cell transplant. Imatinib dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), IRRADIATION (View Irradiation Review and Irradiation Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (Unk) (View Cytarabine Review and Cytarabine Label ), MITOXANTRONE (Unk) (View Mitoxantrone Review and Mitoxantrone Label ), ETOPOSIDE (Unk) (View Etoposide Review and Etoposide Label ).

6844806-8 | Acute Lymphocytic Leukaemia Recurrent, Bone Marrow Transplant
Patient was taking Imatinib (View Usage). Patient had the following side effects: acute lymphocytic leukaemia recurrent, bone marrow transplant (What is bone marrow transplant?) on Jul 01, 2010 from KOREA, REPUBLIC OF Additional patient health information: Male patient , 55 years of age, was diagnosed with acute lymphocytic leukaemia, prophylaxis against graft versus host disease and. Imatinib dosage: . During the same period patient was treated with BUSULFAN (View Busulfan Review and Busulfan Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ANTITHYMOCYTE IMMUNOGLOBULIN (View Antithymocyte Immunoglobulin Review and Antithymocyte Immunoglobulin Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6844800-7 | Acute Lymphocytic Leukaemia Recurrent, Bone Marrow Transplant
Adverse event was reported on Jul 01, 2010 by a Female patient taking Imatinib (View Usage) (Dosage: Unk) was diagnosed with acute lymphocytic leukaemia, graft versus host disease and. Location: KOREA, REPUBLIC OF , 36 years of age, After Imatinib was administered, patient had the following side effects: acute lymphocytic leukaemia recurrent, bone marrow transplant (What is bone marrow transplant?). During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), IRRADIATION (View Irradiation Review and Irradiation Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6826237-X | Chromosome Analysis Abnormal, Chronic Myeloid Leukaemia Transformation, Debridement, Disseminated Intravascular Coagulation, Infection, Leukaemia Recurrent, Leukocytosis, Leukopenia, Marrow Hyperplasia
on Jun 24, 2010 Female patient from JAPAN , 69 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: chromosome analysis abnormal, chronic myeloid leukaemia transformation, debridement, disseminated intravascular coagulation, infection (What is infection?), leukaemia recurrent, leukocytosis, leukopenia, marrow hyperplasia. Imatinib dosage: 400 Mg, Unk. During the same period patient was treated with ALL TRANS RETINOIC ACID (45 Mg/m2) (View All Trans Retinoic Acid Review and All Trans Retinoic Acid Label ).

6802811-1 | Chromosome Analysis Abnormal, Graft Versus Host Disease, Leukaemia Recurrent
on Jun 17, 2010 Female patient from JAPAN , 16 years of age, was treated with Imatinib (View Usage). Patient had the following side effects: chromosome analysis abnormal, graft versus host disease, leukaemia recurrent. Imatinib dosage: 300 Mg, Unk. During the same period patient was treated with CYCLOPHOSPHAMIDE (6 G, Unk) (View Cyclophosphamide Review and Cyclophosphamide Label ), RADIATION TREATMENT (14.4 Gy, Unk) (View Radiation Treatment Review and Radiation Treatment Label ).

6795019-X | Abdominal Pain, Blood Creatinine Increased, Intentional Overdose, Major Depression, Mood Altered, Psychomotor Retardation, Suicide Attempt, Troponin Increased, Vomiting
Patient was taking Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), blood creatinine increased, intentional overdose, major depression, mood altered, psychomotor retardation, suicide attempt, troponin increased, vomiting on Jun 14, 2010 from FRANCE Additional patient health information: Female patient , 53 years of age, was diagnosed with chronic myeloid leukaemia, hypothyroidism and. Imatinib dosage: 400 Mg, Bid. During the same period patient was treated with LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ). Patient was hospitalized.

6786343-5 | Disease Progression, Pulmonary Veno-occlusive Disease, Treatment Failure
Adverse event was reported on May 13, 2010 by a Female patient taking Imatinib (View Usage) (Dosage: 400 Mg, Qd) was diagnosed with pulmonary veno-occlusive disease and. Location: TURKEY , 34 years of age, Patient experienced the following unwanted or unexpected effects: disease progression, pulmonary veno-occlusive disease, treatment failure. During the same period patient was treated with SILDENAFIL CITRATE (2x25 Mg) (View Sildenafil Citrate Review and Sildenafil Citrate Label ).

6785727-9 | Chromosome Analysis Abnormal, Graft Versus Host Disease, Leukaemia Recurrent
on Jun 17, 2010 Female patient from JAPAN , 16 years of age, was treated with Imatinib (View Usage). Patient had the following side effects: chromosome analysis abnormal, graft versus host disease, leukaemia recurrent. Imatinib dosage: 300 Mg, Unk. During the same period patient was treated with CYCLOPHOSPHAMIDE (6 G, Unk) (View Cyclophosphamide Review and Cyclophosphamide Label ), RADIATION TREATMENT (14.4 Gy, Unk) (View Radiation Treatment Review and Radiation Treatment Label ).

6768130-7 | Abdominal Pain, Ascites, Explorative Laparotomy, Gastrointestinal Stromal Tumour, Gene Mutation Identification Test Positive, Hepatic Failure, Inferior Vena Caval Occlusion, Liver Function Test Abnormal, Malignant Neoplasm Progression
on Jun 08, 2010 Male patient from GERMANY , 52 years of age, was diagnosed with metastases to liver and was treated with Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), ascites, explorative laparotomy, gastrointestinal stromal tumour, gene mutation identification test positive, hepatic failure, inferior vena caval occlusion, liver function test abnormal, malignant neoplasm progression. Imatinib dosage: 400 Mg, Daily. During the same period patient was treated with SUNITINIB MALATE (50 Mg, Daily) (View Sunitinib Malate Review and Sunitinib Malate Label ).

6763061-0 | Klebsiella Infection, Multi-organ Failure, Septic Shock
Patient was taking Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: klebsiella infection, multi-organ failure, septic shock on Jun 03, 2010 from HUNGARY Additional patient health information: Male patient , child 12 years of age, was diagnosed with acute lymphocytic leukaemia and. Imatinib dosage: 400 Mg/day. During the same period patient was treated with CYCLOSPORINE (2x125 Mg/day) (View Cyclosporine Review and Cyclosporine Label ).

6762654-4 | Gene Mutation Identification Test Positive, Myelofibrosis, Splenomegaly, Thrombocytosis
Adverse event was reported on May 26, 2010 by a Female patient taking Imatinib (View Usage) (Dosage: 400 Mg, Daily) was diagnosed with chronic myeloid leukaemia and. Location: FRANCE , 82 years of age, Patient had the following side effects: gene mutation identification test positive, myelofibrosis, splenomegaly, thrombocytosis. During the same period patient was treated with HYDROXYCARBAMIDE (Unk) (View Hydroxycarbamide Review and Hydroxycarbamide Label ), SALICYLIC ACID (Unk) (View Salicylic Acid Review and Salicylic Acid Label ).

6762652-0 | Abdominal Pain, Back Pain, Bile Duct Stenosis, Chest Pain, Cholangitis, Cholecystectomy, Laparoscopy, Sepsis, Small Intestinal Obstruction
on May 26, 2010 Male patient from UNITED STATES , weighting 138.9 lb, was diagnosed with gastrointestinal stromal tumour and was treated with Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), back pain (What is back pain?), bile duct stenosis, chest pain (What is chest pain?), cholangitis, cholecystectomy, laparoscopy, sepsis (What is sepsis?), small intestinal obstruction. Imatinib dosage: 200 Mg, Qd. During the same period patient was treated with SUNITINIB MALATE (Unk) (View Sunitinib Malate Review and Sunitinib Malate Label ). Patient was hospitalized.

6762320-5 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Autoantibody Positive, Autoimmune Hepatitis, Hepatic Necrosis
on May 26, 2010 Male patient from ITALY , 65 years of age, was diagnosed with gastrointestinal stromal tumour and was treated with Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, autoantibody positive, autoimmune hepatitis, hepatic necrosis. Imatinib dosage: 400 Mg/day.

6762022-5 | Stem Cell Transplant, Therapeutic Response Decreased, Treatment Failure
Patient was taking Imatinib (View Usage). Patient had the following side effects: stem cell transplant, therapeutic response decreased, treatment failure on May 27, 2010 from CHINA Additional patient health information: Female patient , 36 years of age, was diagnosed with chronic myeloid leukaemia and. Imatinib dosage: .

6762021-3 | Gene Mutation Identification Test Positive, Stem Cell Transplant, Therapeutic Response Decreased, Treatment Failure
Adverse event was reported on May 27, 2010 by a Female patient taking Imatinib (View Usage) (Dosage: ) was diagnosed with chronic myeloid leukaemia and. Location: CHINA , 28 years of age, After Imatinib was administered, patient had the following side effects: gene mutation identification test positive, stem cell transplant, therapeutic response decreased, treatment failure.

6762020-1 | Stem Cell Transplant, Therapeutic Response Decreased, Treatment Failure
on May 27, 2010 Male patient from CHINA , 44 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: stem cell transplant, therapeutic response decreased, treatment failure. Imatinib dosage: .

6762019-5 | Stem Cell Transplant, Therapeutic Response Decreased, Treatment Failure
on May 27, 2010 Male patient from CHINA , 34 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). Patient had the following side effects: stem cell transplant, therapeutic response decreased, treatment failure. Imatinib dosage: .

6762018-3 | Stem Cell Transplant, Therapeutic Response Decreased, Treatment Failure
Patient was taking Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: stem cell transplant, therapeutic response decreased, treatment failure on May 27, 2010 from CHINA Additional patient health information: Male patient , 51 years of age, was diagnosed with chronic myeloid leukaemia and. Imatinib dosage: .

6762012-2 | Gene Mutation Identification Test Positive, Stem Cell Transplant, Therapeutic Response Decreased, Treatment Failure
Adverse event was reported on May 27, 2010 by a Male patient taking Imatinib (View Usage) (Dosage: ) was diagnosed with chronic myeloid leukaemia and. Location: CHINA , 30 years of age, Patient experienced the following unwanted or unexpected effects: gene mutation identification test positive, stem cell transplant, therapeutic response decreased, treatment failure.

6758909-X | Encephalopathy, Hepatic Failure, Liver Function Test Abnormal, Serum Ferritin Increased
on Jun 01, 2010 Female patient from UNITED KINGDOM , 59 years of age, was diagnosed with dermatofibrosarcoma and was treated with Imatinib (View Usage). Patient had the following side effects: encephalopathy, hepatic failure, liver function test abnormal, serum ferritin increased. Imatinib dosage: 400 Mg, Qd. Patient was hospitalized.

6757804-X | Bone Marrow Transplant, Therapeutic Response Decreased
on May 24, 2010 Male patient from ITALY , 50 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: bone marrow transplant (What is bone marrow transplant?), therapeutic response decreased. Imatinib dosage: .

6756179-X | Bone Marrow Transplant, Therapeutic Response Decreased
Patient was taking Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow transplant (What is bone marrow transplant?), therapeutic response decreased on May 24, 2010 from ITALY Additional patient health information: Male patient , 45 years of age, was diagnosed with chronic myeloid leukaemia and. Imatinib dosage: .

6753480-0 | Therapeutic Response Decreased, Treatment Failure
Adverse event was reported on May 27, 2010 by a Female patient taking Imatinib (View Usage) (Dosage: ) was diagnosed with chronic myeloid leukaemia and. Location: CHINA , 33 years of age, Patient had the following side effects: therapeutic response decreased, treatment failure.

6753472-1 | Abdominal Pain, Back Pain, Bile Duct Stenosis, Chest Pain, Cholangitis, Cholecystectomy, Laparoscopy, Sepsis, Small Intestinal Obstruction
on May 26, 2010 Male patient from UNITED STATES , weighting 138.9 lb, was diagnosed with gastrointestinal stromal tumour and was treated with Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), back pain (What is back pain?), bile duct stenosis, chest pain (What is chest pain?), cholangitis, cholecystectomy, laparoscopy, sepsis (What is sepsis?), small intestinal obstruction. Imatinib dosage: 200mg. During the same period patient was treated with SUNITINIB MALATE (Unk) (View Sunitinib Malate Review and Sunitinib Malate Label ). Patient was hospitalized.

6752589-5 | Infection, Stem Cell Transplant, Therapeutic Response Decreased, Treatment Failure
on May 27, 2010 Male patient from CHINA , 23 years of age, was treated with Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: infection (What is infection?), stem cell transplant, therapeutic response decreased, treatment failure. Imatinib dosage: .

6752588-3 | Graft Versus Host Disease, Stem Cell Transplant, Therapeutic Response Decreased, Treatment Failure
Patient was taking Imatinib (View Usage). Patient had the following side effects: graft versus host disease, stem cell transplant, therapeutic response decreased, treatment failure on May 27, 2010 from CHINA Additional patient health information: Male patient , 48 years of age, was diagnosed with chronic myeloid leukaemia and. Imatinib dosage: .

6751767-9 | Chest Pain, Dyspnoea Exertional, Ejection Fraction Decreased, Endocardial Fibrosis, Endocarditis Fibroplastica, Intracardiac Thrombus
Adverse event was reported on May 20, 2010 by a Male patient taking Imatinib (View Usage) (Dosage: 100 Mg Daily) was diagnosed with hypereosinophilic syndrome and. Location: CZECH REPUBLIC , 32 years of age, After Imatinib was administered, patient had the following side effects: chest pain (What is chest pain?), dyspnoea exertional, ejection fraction decreased, endocardial fibrosis, endocarditis fibroplastica, intracardiac thrombus. During the same period patient was treated with PREDNISONE TAB (1 Mg/kg, Unk) (View Prednisone Tab Review and Prednisone Tab Label ), WARFARIN SODIUM (Unk) (View Warfarin Sodium Review and Warfarin Sodium Label ), CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ).

6751763-1 | Ascites, Hepatosplenomegaly, Pericardial Effusion, Pleural Effusion
on May 20, 2010 Male patient from LEBANON , 38 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: ascites, hepatosplenomegaly, pericardial effusion, pleural effusion. Imatinib dosage: 400 Mg/day.

6747608-6 | Choroiditis, Eye Infection Toxoplasmal, Visual Acuity Reduced
on May 17, 2010 Male patient from INDIA , 48 years of age, was treated with Imatinib (View Usage). Patient had the following side effects: choroiditis, eye infection toxoplasmal, visual acuity reduced. Imatinib dosage: Unk.

6747017-X | Blast Crisis In Myelogenous Leukaemia, Chronic Myeloid Leukaemia Transformation, Leukaemia Basophilic
Patient was taking Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: blast crisis in myelogenous leukaemia, chronic myeloid leukaemia transformation, leukaemia basophilic on May 17, 2010 from UNITED STATES Additional patient health information: Female patient , 39 years of age, was diagnosed with chronic myeloid leukaemia and. Imatinib dosage: 800 Mg/day. During the same period patient was treated with NILOTINIB (600 Mg, Bid) (View Nilotinib Review and Nilotinib Label ), TIPIFARNIB (View Tipifarnib Review and Tipifarnib Label ), DASATINIB (70 Mg, Bid) (View Dasatinib Review and Dasatinib Label ). Patient was hospitalized.

6735451-3 | Hepatic Failure, Stem Cell Transplant, Venoocclusive Liver Disease
Adverse event was reported on May 17, 2010 by a Female patient taking Imatinib (View Usage) (Dosage: ) was diagnosed with acute lymphocytic leukaemia and. Location: JAPAN , child 4 years of age, weighting 30.86 lb, Patient experienced the following unwanted or unexpected effects: hepatic failure, stem cell transplant, venoocclusive liver disease. During the same period patient was treated with HYPER CVAD (View Hyper-cvad Review and Hyper-cvad Label ), BUSULFEX (1.2 Mg/kg, Unk) (View Busulfex Review and Busulfex Label ).

6735434-3 | Splenomegaly
on May 10, 2010 Female patient from CZECH REPUBLIC , 61 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). Patient had the following side effects: splenomegaly. Imatinib dosage: 400 Mg/day.

6732606-9 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Gamma-glutamyltransferase Increased, Hyperbilirubinaemia
on May 12, 2010 Male patient from UNITED STATES , 43 years of age, weighting 208.3 lb, was diagnosed with gastrointestinal stromal tumour and was treated with Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, hyperbilirubinaemia. Imatinib dosage: 400 Mg, Qd. During the same period patient was treated with SUNITINIB MALATE (25 Mg, Qd) (View Sunitinib Malate Review and Sunitinib Malate Label ), ENALAPRIL (Unk) (View Enalapril Review and Enalapril Label ).

6732595-7 | Abdominal Tenderness, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Aspiration Pleural Cavity, Biliary Dilatation, Blood Albumin Decreased, Blood Alkaline Phosphatase Increased, Blood Glucose Increased, C-reactive Protein Increased
Patient was taking Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal tenderness, alanine aminotransferase increased, aspartate aminotransferase increased, aspiration pleural cavity, biliary dilatation, blood albumin decreased, blood alkaline phosphatase increased, blood glucose increased, c-reactive protein increased on May 06, 2010 from INDIA Additional patient health information: Male patient , 53 years of age, was diagnosed with chronic myeloid leukaemia, diabetes mellitus, hypertension and. Imatinib dosage: Unk. During the same period patient was treated with METFORMIN HYDROCHLORIDE (500 Mg, Bid) (View Metformin Hydrochloride Review and Metformin Hydrochloride Label ), AMLODIPINE (5 Mg, Qd) (View Amlodipine Review and Amlodipine Label ). Patient was hospitalized.

6702859-1 | Haematemesis, Nausea
Adverse event was reported on Apr 29, 2010 by a Male patient taking Imatinib (View Usage) (Dosage: 400 Mg Every Day Po) was diagnosed with chronic myeloid leukaemia and. Location: UNITED STATES , 85 years of age, Patient had the following side effects: haematemesis, nausea (What is nausea?). Patient was hospitalized.

6686931-0 | Confusional State, Headache, Metastases To Central Nervous System, Metastases To Lung, Nausea, Neoplasm Malignant, Orchidectomy, Pancytopenia
on Apr 08, 2010 Male patient from POLAND , 30 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). After Imatinib was administered, patient had the following side effects: confusional state, headache (What is headache?), metastases to central nervous system, metastases to lung, nausea (What is nausea?), neoplasm malignant, orchidectomy, pancytopenia. Imatinib dosage: 400 Mg/day. Patient was hospitalized.

6679528-X | Chromosome Analysis Abnormal, Chronic Myeloid Leukaemia, No Therapeutic Response, Stem Cell Transplant
on Mar 31, 2010 Male patient from IRELAND , 36 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Imatinib (View Usage). Patient experienced the following unwanted or unexpected effects: chromosome analysis abnormal, chronic myeloid leukaemia, no therapeutic response, stem cell transplant. Imatinib dosage: 400 Mg, Unk. During the same period patient was treated with NILOTINIB (400 Mg, Bid) (View Nilotinib Review and Nilotinib Label ).

6679492-3 | Abdominal Neoplasm, Fatigue, Lymphoproliferative Disorder, Periorbital Oedema
Patient was taking Imatinib (View Usage). Patient had the following side effects: abdominal neoplasm, fatigue, lymphoproliferative disorder, periorbital oedema on Mar 31, 2010 from GERMANY Additional patient health information: Male patient , 71 years of age, . Imatinib dosage: 400 Mg Daily.